Johnson & Johnson Debuts NEW Full Visual Range Presbyopia Correcting IOL TECNIS Odyssey at the 2024 ASCRS Annual Meeting

Strong data shows TECNIS Odyssey Intraocular Lens (IOL) offers patients full visual range,* high contrast quality and enhanced tolerance to residual refractive error.1,2,3,4,5,6,7 

Research shows higher prevalence of cataracts among Black, Hispanic and Chinese Americans, despite lower rates of cataract surgery within these groups.8

JACKSONVILLE, FL., March 28, 2024 – Johnson & Johnson will give an exclusive preview of its NEW presbyopia correcting IOL, TECNIS Odyssey, at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA, April 5-8. This cutting-edge technology is designed to provide full visual range, reduced night vision symptoms, and best-in-category contrast and low-light performance.1,9,10,11 Among 28 company-sponsored and investigator-led studies showcased at the meeting, five will focus on the real-world outcomes delivered by TECNIS Odyssey, led by surgeons with early access to the technology. TECNIS Odyssey is expected to be fully commercially available in the US during the second half of 2024.

In a series of professional educational offerings and peer-led discussions, found here, key opinion leaders who have experience implanting TECNIS Odyssey will share their experiences, insights and data gathered ahead of the full market release later this year.

“The introduction of TECNIS Odyssey marks a significant leap forward in our mission to make vision possible for more patients in the United States.” said Lori Tierney, President of Americas, Johnson & Johnson Vision. “At this year's ASCRS meeting we are proud to provide Ophthalmologists a preview of our latest technology, backed by data, aimed at delivering sharp and high-quality vision for cataract patients at all distances, in all lighting conditions.”

“I had the privilege to be the first surgeon in the world to implant this IOL and since then, it has become my go to solution for high quality full range of vision and for those patients who want as much reading vision as possible.” said Elizabeth Yeu, MD, Norfolk, VA.§

Johnson & Johnson’s commitment to ophthalmology goes beyond developing groundbreaking solutions like TECNIS Odyssey. In addition to showcasing their latest innovation, data from the DEI Disparity Index Program investigating evidence-based racial, ethnic and gender-related disparities in access to cataract surgery in the U.S. will also be highlighted. Johnson & Johnson will continue the conversation in booth discussions aimed at addressing and mitigating these disparities, speaking to its bold ambition to pave the way for a new future of eye health for all: Vision Made Possible.

Key data highlights positive outcomes with TECNIS Odyssey IOL

These findings demonstrate that the newest PC-IOL provides a full range of vision, as well as high image quality and tolerance to residual refractive error as compared to existing multifocal and hybrid presbyopia correcting IOLs1.

  1. Electronic Poster. “Introduction of a Next Generation Presbyopia Correcting IOL.” Soscia W. Friday, April 5, 2024, 8:10 PM – 8:20 PM, BCEC. (Abstract #50695
  2. Paper Presentation. “Tolerance to Refractive Error of a Next Generation Presbyopia Correcting IOL.” Al-Mohtaseb Z. Saturday, April 6, 2024, 4:15 PM – 4:20 PM, BCEC – Meeting Level 2, Room 256.
  3. Paper Presentation. “Clinical Evaluation of Tolerance to Residual Refractive Errors Following Implantation with New Diffractive Presbyopia Correcting IOL.” Chang D. Saturday, April 6, 2024, 11:05 AM – 11:10 AM, BCEC – Meeting Level 2, Room 295B.(Abstract #50694)

The results suggest TECNIS Odyssey demonstrates full visual range from distance to near vision with minimal visual complaints and a high rate of being spectacle-free1

  1. Paper Presentation. “Depth of Focus and Spectacle Independence 1-Month Outcomes for a New Full-Range Spectacle Independence IOL.” Waring G. Saturday, April 6, 2024, 10:40 AM – 10:45 AM, BCEC – Meeting Level 2, Room 256. (Abstract #50686)
  2. Paper Presentation. “Real World Evidence Visual Outcomes of a New Full-Range Spectacle-Independence Intraocular Lens.” Mathews P. Saturday, April 6, 2024, 11:15 AM – 11:20 AM, BCEC – Meeting Level 2, Room 295B. (Abstract #50685)

All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.


About Vision at Johnson & Johnson

Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. As a global leader in eye-health, we have a bold ambition: Vision Made Possible – and are paving the way for a new future of eye health to support the full spectrum of pediatric, developed and mature eyes. Through cutting-edge innovation, scientific expertise, and advanced technologies, we are revolutionizing the way people see and experience the world. At every step of the eye health journey – from investigational gene therapies for retinal diseases to contact lenses and refractive and cataract surgical solutions – we stand as a trusted partner with the goal of making vision possible for customers and patients. Visit us at follow @JNJVision on Twitter Johnson & Johnson Vision on LinkedIn @JNJVision on Facebook

About Johnson & Johnson MedTech

At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

Media Contacts

Maria Echeverria
Johnson & Johnson Vision

Rx Only

The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Odyssey™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only.


Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder.If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design.


Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Odyssey™ Toric II IOL for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The effectiveness of TECNIS Odyssey™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Odyssey™ IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism.


Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

*According to ISO 11979-7:2024, based on the clinical study of the parent IOL.
Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.<

Lori Tierney is an employee of Johnson & Johnson Vision, Inc., serving as President, Americas.

§Elizabeth Yeu is an employee of Virginia Eye Consultants, as well as the President of the American Society of Cataract and Refractive Surgery.

Johnson & Johnson MedTech comprises the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.



© Johnson & Johnson Surgical Vision, Inc. 2023. All rights reserved.


1 Data on File, 2024. 2024DOF4002

2 Mathews, P., Gounou, F., Jenkins, M., De Jesus, M., & Weeber, H. (2023). Introduction of a new next generation presbyopia correcting IOL.

3 Al-Mohtaseb, Z., Alarcon, A., Gounou, F., De Jesus, M., & Weeber, H. (2023). Tolerance to refractive error of a next generation presbyopia correcting IOL.

4 Muenz, D., De Jesus, M., Weeber, H., Vilupuru, V., & Tsai, L. (2023). Clinical evaluation of tolerance to residual refractive errors following implantation with a new diffractive presbyopia correcting IOL.

5 Muenz, D., De Jesus, M., & Weeber, H. (2023). Depth of focus and Spectacle independence 1-Month Outcomes for a new full-range spectacle independence IOL.

6 Muenz, D., De Jesus, M., Weeber, H., & Mathews, P. (2023). Real World Evidence visual outcomes of a new full-range spectacle-independence intraocular lens.

7 Data on File, 2023. DOF2023CT4031

8 Pastuck, T. (2023). Evidence-Based Disparities in Care Metrics and Outcomes Along the Continuum of Cataract Care in the United States.

9 Data on File, 2023. DOF2023CT4050

10 Data on File, 2023. DOF2023CT4051

11 Data on File, 2023. DOF2023CT4007